Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis Presented ByProf. Raymond Comenzo, Tufts University, USA TrialPhase 3, ANDROMEDA ConferenceEHA 2019 9 August, 2019 19:40